Chronic Spontaneous UrticariaPhase 1NCT06294288
A Study of Single and Multiple Doses of LP-003 in Healthy Adult Participants
A Phase 1 study testing LP-003 Dose 1 (Single), LP-003 Dose 2 (Single) and LP-003 Dose 3 (Single) in people with Chronic Spontaneous Urticaria, run by Longbio Pharma at 1 site in China.
Trial summary
The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-003 in healthy volunteers. The study will be conducted in 2 parts: Part 1, the single ascending dose (SAD) is the first in human (FIH) study of LP-003 and Part 2, multiple ascending… Read more about this study
- Who is it for?
- Ages 18 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Chronic Spontaneous Urticaria
- What is being tested?
- LP-003 Dose 1 (Single), LP-003 Dose 2 (Single) and LP-003 Dose 3 (Single)
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteChina
- Study dates
- 13 Jul 2022to 4 Mar 2024
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy males or females aged 18 through 50 years
- Male subjects must weigh ≥50 kg, and female subjects must weigh ≥45 kg, with a BMI between 19.0 and 28.0 kg/m² (inclusive).
- Male subjects and their partners or female subjects must agree to use one or more non-pharmaceutical contraceptive methods (such as total abstinence, condoms, Iuds, partner ligation, etc.) during the trial period and for 6 months after the trial, and do not plan to donate sperm or eggs.
- The subjects fully understand the purpose, nature, method and possible adverse reactions of the experiment, and voluntarily participate in the experiment and sign the informed consent.
- The subjects were able to communicate well with the researchers and complete the study according to the protocol.
Who cannot join
- People who are allergic to the experimental drug and any of its excipients, have a history of allergy to monoclonal antibodies, and are allergic to multiple drugs and food.
- Patients who have been or are currently suffering from any clinically serious diseases such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, urogenital system, hematology, immunology, psychiatric and metabolic abnormalities, or any other diseases that can interfere with the test results.
- Patients who had undergone surgery within 3 months before the trial that the researchers judged would affect drug absorption, distribution, metabolism, and excretion, or had surgery within 4 weeks prior to the trial, or planned to have surgery during the study period.
- Any history of infection within 14 days prior to administration.
- A person who is currently infected with parasites or has traveled to an endemic area within the last 3 months or 24 weeks prior to administration.
- Pregnant and lactating women.
Show all 10Show fewer
- Hepatitis B surface antigen, hepatitis C virus antibodies, human immunodeficiency virus antibodies, treponema pallidum antibodies A positive person.
- Patients who have received any biological agent (including antibodies or derivatives such as omalizumab) within 16 weeks prior to administration (or 5 half-lives, selecting the longer time period).
- Participants who had participated in other clinical trials within 3 months prior to screening.
- The investigator deems any condition unsuitable for study participation.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of LP-003 in Healthy Volunteers
The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-003 in healthy volunteers. The study will be conducted in 2 parts: Part 1, the single ascending dose (SAD) is the first in human (FIH) study of LP-003 and Part 2, multiple ascending dose (MAD).
- Conditions
- Chronic Spontaneous Urticaria
- Being tested
- LP-003 Dose 1 (Single), LP-003 Dose 2 (Single), LP-003 Dose 3 (Single), LP-003 Dose 4 (Single), LP-003 Dose 5 (Single)
- Medical subject headings
- Chronic Urticaria
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LP-003 Dose 1 (Single)Biological
A single dose of LP-003 (Dose 1) was administered intravenously.
LP-003 Dose 2 (Single)Biological
A single dose of LP-003 (Dose 2) was administered intravenously.
LP-003 Dose 3 (Single)Biological
A single dose of LP-003 (Dose 3) was administered intravenously.
LP-003 Dose 4 (Single)Biological
A single dose of LP-003 (Dose 4) was administered intravenously.
LP-003 Dose 5 (Single)Biological
A single dose of LP-003 (Dose 5) was administered intravenously.
Placebo (Single)Biological
A single dose of placebo was administered intravenously.
LP-003 Dose 6 (Multiple)Biological
LP-003 (Dose 6) was administered multiple times subcutaneously.
LP-003 Dose 7 (Multiple)Biological
LP-003 (Dose 7) was administered multiple times subcutaneously.
LP-003 Dose 8 (Multiple)Biological
LP-003 (Dose 8) was administered multiple times subcutaneously.
Placebo (Multiple)Biological
Placebo was administered multiple times subcutaneously.
| Study group | Role | What they receive |
|---|---|---|
| Cohort 1: LP-003 Dose 1 (Single) | Experimental | Not described Receives: Biological: LP-003 Dose 1 (Single) |
| Cohort 2: LP-003 Dose 2 (Single) | Experimental | Not described Receives: Biological: LP-003 Dose 2 (Single) |
| Cohort 3: LP-003 Dose 3 (Single) | Experimental | Not described Receives: Biological: LP-003 Dose 3 (Single) |
| Cohort 4: LP-003 Dose 4 (Single) | Experimental | Not described Receives: Biological: LP-003 Dose 4 (Single) |
| Cohort 5: LP-003 Dose 5 (Single) | Experimental | Not described Receives: Biological: LP-003 Dose 5 (Single) |
| Cohort 6: Placebo (Single) | Placebo comparator | Not described Receives: Biological: Placebo (Single) |
| Cohort 7: LP-003 Dose 6 (Multiple) | Experimental | Not described Receives: Biological: LP-003 Dose 6 (Multiple) |
| Cohort 8: LP-003 Dose 7 (Multiple) | Experimental | Not described Receives: Biological: LP-003 Dose 7 (Multiple) |
| Cohort 9: LP-003 Dose 8 (Multiple) | Experimental | Not described Receives: Biological: LP-003 Dose 8 (Multiple) |
| Cohort 10: Placebo (Multiple) | Placebo comparator | Not described Receives: Biological: Placebo (Multiple) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Adverse events
Number of subjects with treatment-related Treatment Emergent Adverse Events (TEAEs).
Measured: Observation for 280 days after administration
Secondary outcomes (8)
Time to peak concentration (Tmax) of LP-003
The time when the blood drug concentration reaches its peak after a single dose of medication.
Measured: Observation for 280 days after administration
Maximum concentration (Cmax) of LP-003
The maximum concentration of LP-003 in the bloodstream after administration.
Measured: Observation for 280 days after administration
Elimination half-life (t1/2) of LP-003
The time required for the concentration of LP-003 in the bloodstream to decrease by half.
Measured: Observation for 280 days after administration
Area under the concentration-time curve (AUC0-t) of LP-003
The area under the concentration-time curve (AUC) from time zero to the last chosen time point represents the integral of the drug concentration in the bloodstream over the specified duration.
Measured: Observation for 280 days after administration
Apparent clearance rate (CL/F) of LP-003
The ratio of drug clearance to drug concentration, represents the apparent clearance of a drug after administration, adjusted for bioavailability.
Measured: Observation for 280 days after administration
Assessment of immunogenicity
The proportion of anti drug antibody (ADA) positive subjects at different detection time points.
Measured: Observation for 280 days after administration
Assessment of total immunoglobulin E (IgE)
The changes in serum total immunoglobulin E (IgE) levels compared to baseline at different assessment time points.
Measured: Observation for 168 days after administration
Assessment of free IgE
The changes in serum free IgE levels compared to baseline at different assessment time points.
Measured: Observation for 168 days after administration
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Mar 2024
- Study start13 Jul 2022
- Primary completion4 Mar 2024
- Study completion4 Mar 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Spontaneous UrticariaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Longbio Pharma
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Xueying Ding, Principal investigator, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06294288
- Sponsor's protocol ID
- P-10-LP003-2022-01
- Status last verified
- Dec 2025
- First submitted
- 20 Feb 2024
- Last updated
- 12 Dec 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Doses of LP-003 in Healthy Volunteers
- ClinicalTrials.gov ID
- NCT06294288
- Acronym / sponsor ID
- P-10-LP003-2022-01
- Conditions
- Chronic Spontaneous Urticaria
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Longbio PharmaIndustry (pharma, biotech, devices)
- Study start
- 13 Jul 2022 (actual)
- Primary completion
- 4 Mar 2024 (actual)
- Study completion
- 4 Mar 2024 (actual)
- First posted
- 5 Mar 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-003 in healthy volunteers. The study will be conducted in 2 parts: Part 1, the single ascending dose (SAD) is the first in human (FIH) study of LP-003 and Part 2, multiple ascending dose (MAD).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 10
| Arm | Type | Receives |
|---|---|---|
| Cohort 1: LP-003 Dose 1 (Single) | Experimental | Biological: LP-003 Dose 1 (Single) |
| Cohort 2: LP-003 Dose 2 (Single) | Experimental | Biological: LP-003 Dose 2 (Single) |
| Cohort 3: LP-003 Dose 3 (Single) | Experimental | Biological: LP-003 Dose 3 (Single) |
| Cohort 4: LP-003 Dose 4 (Single) | Experimental | Biological: LP-003 Dose 4 (Single) |
| Cohort 5: LP-003 Dose 5 (Single) | Experimental | Biological: LP-003 Dose 5 (Single) |
| Cohort 6: Placebo (Single) | Placebo comparator | Biological: Placebo (Single) |
| Cohort 7: LP-003 Dose 6 (Multiple) | Experimental | Biological: LP-003 Dose 6 (Multiple) |
| Cohort 8: LP-003 Dose 7 (Multiple) | Experimental | Biological: LP-003 Dose 7 (Multiple) |
| Cohort 9: LP-003 Dose 8 (Multiple) | Experimental | Biological: LP-003 Dose 8 (Multiple) |
| Cohort 10: Placebo (Multiple) | Placebo comparator | Biological: Placebo (Multiple) |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Healthy males or females aged 18 through 50 years
- Male subjects must weigh ≥50 kg, and female subjects must weigh ≥45 kg, with a BMI between 19.0 and 28.0 kg/m² (inclusive).
- Male subjects and their partners or female subjects must agree to use one or more non-pharmaceutical contraceptive methods (such as total abstinence, condoms, Iuds, partner ligation, etc.) during the trial period and for 6 months after the trial, and do not plan to donate sperm or eggs.
- The subjects fully understand the purpose, nature, method and possible adverse reactions of the experiment, and voluntarily participate in the experiment and sign the informed consent.
- The subjects were able to communicate well with the researchers and complete the study according to the protocol.
Key exclusion criteria (10 listed)
- People who are allergic to the experimental drug and any of its excipients, have a history of allergy to monoclonal antibodies, and are allergic to multiple drugs and food.
- Patients who have been or are currently suffering from any clinically serious diseases such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, urogenital system, hematology, immunology, psychiatric and metabolic abnormalities, or any other diseases that can interfere with the test results.
- Patients who had undergone surgery within 3 months before the trial that the researchers judged would affect drug absorption, distribution, metabolism, and excretion, or had surgery within 4 weeks prior to the trial, or planned to have surgery during the study period.
- Any history of infection within 14 days prior to administration.
- A person who is currently infected with parasites or has traveled to an endemic area within the last 3 months or 24 weeks prior to administration.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LP-003 Dose 1 (Single)A single dose of LP-003 (Dose 1) was administered intravenously. | Biological | Cohort 1: LP-003 Dose 1 (Single) |
| LP-003 Dose 2 (Single)A single dose of LP-003 (Dose 2) was administered intravenously. | Biological | Cohort 2: LP-003 Dose 2 (Single) |
| LP-003 Dose 3 (Single)A single dose of LP-003 (Dose 3) was administered intravenously. | Biological | Cohort 3: LP-003 Dose 3 (Single) |
| LP-003 Dose 4 (Single)A single dose of LP-003 (Dose 4) was administered intravenously. | Biological | Cohort 4: LP-003 Dose 4 (Single) |
| LP-003 Dose 5 (Single)A single dose of LP-003 (Dose 5) was administered intravenously. | Biological | Cohort 5: LP-003 Dose 5 (Single) |
| Placebo (Single)A single dose of placebo was administered intravenously. | Biological | Cohort 6: Placebo (Single) |
| LP-003 Dose 6 (Multiple)LP-003 (Dose 6) was administered multiple times subcutaneously. | Biological | Cohort 7: LP-003 Dose 6 (Multiple) |
| LP-003 Dose 7 (Multiple)LP-003 (Dose 7) was administered multiple times subcutaneously. | Biological | Cohort 8: LP-003 Dose 7 (Multiple) |
| LP-003 Dose 8 (Multiple)LP-003 (Dose 8) was administered multiple times subcutaneously. | Biological | Cohort 9: LP-003 Dose 8 (Multiple) |
| Placebo (Multiple)Placebo was administered multiple times subcutaneously. | Biological | Cohort 10: Placebo (Multiple) |
Primary outcome
Adverse events
Time frame: Observation for 280 days after administration
Number of subjects with treatment-related Treatment Emergent Adverse Events (TEAEs).
8 secondary outcomes
Time to peak concentration (Tmax) of LP-003
Time frame: Observation for 280 days after administration
Maximum concentration (Cmax) of LP-003
Time frame: Observation for 280 days after administration
Elimination half-life (t1/2) of LP-003
Time frame: Observation for 280 days after administration
Area under the concentration-time curve (AUC0-t) of LP-003
Time frame: Observation for 280 days after administration
Apparent clearance rate (CL/F) of LP-003
Time frame: Observation for 280 days after administration
Assessment of immunogenicity
Time frame: Observation for 280 days after administration
Assessment of total immunoglobulin E (IgE)
Time frame: Observation for 168 days after administration
Assessment of free IgE
Time frame: Observation for 168 days after administration
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Dec 2025.
- Individual participant dataSharing planned: No
Related trials for Chronic Spontaneous Urticaria
Not yet recruitingObservational study
Remibrutinib in Real-world Clinical Practice - a South Korea Sub-Study
Chronic Spontaneous Urticaria
Enrolling by invitationPhase 3
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
Chronic Spontaneous Urticaria
RecruitingPhase 2
A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU)
Chronic Spontaneous Urticaria (CSU), Chronic Idiopathic Urticaria
Active, not recruitingEarly Phase 1
A Trial of HRS-3095 in Healthy Volunteers
Chronic Spontaneous Urticaria
RecruitingPhase 2
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
Chronic Spontaneous Urticaria
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Xueying Ding principal investigator
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing LP-003 Dose 1 (Single), LP-003 Dose 2 (Single) and LP-003 Dose 3 (Single) in people with Chronic Spontaneous Urticaria, run by Longbio Pharma at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Adverse events (time frame: Observation for 280 days after administration). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Dec 2025.